Story · Novo Nordisk
Novo Nordisk sues Eli Lilly over weight loss drug advertising
Novo Nordisk filed a lawsuit against rival Eli Lilly on Tuesday in federal district court in New Jersey, accusing the company of false advertising regarding the performance of its weight loss drugs. The lawsuit alleges that Lilly intentionally selected outdated studies to claim that its drugs Mounjaro and Zepbound lead to significantly more weight loss than Novo Nordisk’s Ozempic and other treatments. This legal action highlights the intense competition in the rapidly growing weight loss drug market, where both companies are major players. The case centers on the accuracy of comparative advertising claims, with Novo Nordisk seeking to challenge what it views as misleading marketing tactics by Lilly.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection